Patents by Inventor Rolf Schürmann
Rolf Schürmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9907806Abstract: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.Type: GrantFiled: December 12, 2014Date of Patent: March 6, 2018Assignee: BAYER INTELLECTUAL PROPERTY, GmbHInventors: Bernhard Lindenthal, Rolf Schürmann, Sascha General
-
Patent number: 9592245Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: GrantFiled: December 8, 2014Date of Patent: March 14, 2017Assignee: Bayer Intellectual Property GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20150182540Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6?,7?;15?;16?-dimethylene-3-oxo-17?-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: March 16, 2015Publication date: July 2, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Wolfgang HEIL, Juergen HILMANN, Ralph LIPP, Rolf SCHUERMANN
-
Publication number: 20150105359Abstract: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.Type: ApplicationFiled: December 12, 2014Publication date: April 16, 2015Inventors: Bernhard LINDENTHAL, Rolf SCHÜRMANN, Sascha GENERAL
-
Publication number: 20150094287Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Stephan MLETZKO, Rolf SCHÜRMANN, Kerstin GUDE
-
Patent number: 8921345Abstract: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.Type: GrantFiled: June 10, 2010Date of Patent: December 30, 2014Assignee: Bayer Intellectual Property GmbHInventors: Bernhard Lindenthal, Rolf Schürmann, Sascha General
-
Publication number: 20130140210Abstract: The present invention relates to a low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.5 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the low E2 and DRSP doses it has surprisingly been found that a very high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: June 6, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20130137664Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: May 30, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20120220556Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6?,7?;15?;16?-dimethylene-3-oxo-17?-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: January 23, 2012Publication date: August 30, 2012Inventors: Wolfgang HEIL, Juergen Hilmann, Ralph Lipp, Rolf Schuermann
-
Publication number: 20120172343Abstract: The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions.Type: ApplicationFiled: June 10, 2010Publication date: July 5, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Bernhard Lindenthal, Rolf Schürmann, Sascha General
-
Publication number: 20100093679Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6?,7?;15?;16?-dimethylene-3-oxo-17?-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: December 17, 2009Publication date: April 15, 2010Inventors: Wolfgang HEIL, Juergen Hilmann, Ralph Lipp, Rolf Schuermann
-
Publication number: 20050113350Abstract: A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages.Type: ApplicationFiled: November 26, 2003Publication date: May 26, 2005Inventors: Bernd Duesterberg, Jan Endrikat, Rolf Schuermann
-
Patent number: 6869941Abstract: A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continuous or discontinuous administration of drospirenone and/or the estrogen sulphamate, such as weekly administration of both agents or weekly administration of the estrogen sulphamate and daily administration of the drospirenone.Type: GrantFiled: July 15, 2002Date of Patent: March 22, 2005Assignee: Schering AGInventor: Rolf Schuermann
-
Publication number: 20040009960Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6&bgr;,7&bgr;;15&bgr;;16&bgr;-dimethylene-3-oxo-17&agr;-preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: February 6, 2003Publication date: January 15, 2004Applicant: Schering AktiengesellschaftInventors: Wolfgang Heil, Juergen Hilmann, Ralph Lipp, Rolf Schuermann
-
Publication number: 20030144258Abstract: A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6&bgr;,7&bgr;; 15&bgr;; 16&bgr;-dimethylene-3-oxo-17&agr;-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: February 6, 2003Publication date: July 31, 2003Applicant: Schering AktiengesellschaftInventors: Wolfgang Heil, Juergen Hilmann, Ralph Lipp, Rolf Schuermann
-
Patent number: 6585145Abstract: A Die Bonder or a Wire Bonder contains a device for holding down a substrate. The device comprises a table with drill holes. The drill holes are mechanically programmable with regard to whether vacuum can be applied to them or not. The mechanical programming enables a fast and easy adaptation of the device to different substrates.Type: GrantFiled: December 4, 2001Date of Patent: July 1, 2003Assignee: ESEC Trading SAInventors: Stefan Behler, Beat Zumbuehl, Reto Schubiger, Ruedi Grueter, Rolf Schuermann
-
Publication number: 20030050289Abstract: A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continuous or discontinuous administration of drospirenone and/or the estrogen sulphamate, such as weekly administration of both agents or weekly administration of the estrogen sulphamate and daily administration of the drospirenone.Type: ApplicationFiled: July 15, 2002Publication date: March 13, 2003Applicant: Schering AGInventor: Rolf Schuermann
-
Publication number: 20020132801Abstract: Drospirenone for Hormone Replacement Therapy A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6&bgr;,7&bgr;; 15&bgr;; 16&bgr;-dimethylene-3-oxo-17&agr;-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.Type: ApplicationFiled: January 11, 2001Publication date: September 19, 2002Applicant: Schering AktiengesellschaftInventors: Wolfgang Heil, Juergen Hilmann, Ralph Lipp, Rolf Schuermann
-
Publication number: 20020066765Abstract: A Die Bonder or a Wire Bonder contains a device for holding down a substrate. The device comprises a table with drill holes. The drill holes are mechanically programmable with regard to whether vacuum can be applied to them or not. The mechanical programming enables a fast and easy adaptation of the device to different substrates.Type: ApplicationFiled: December 4, 2001Publication date: June 6, 2002Inventors: Stefan Behler, Beat Zumbuehl, Reto Schubiger, Ruedi Grueter, Rolf Schuermann